HR阳性-话题@MedSci - 梅斯（MedSci）

#HR阳性#

9篇内容 | 1154人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1954157, encodeId=1b9a195415e6c, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=2021年度HR阳性晚期乳腺癌治疗进展总结, objectType=article, longId=732797, objectId=f26ce3279712, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26ce3279712, replyNumber=0, likeNumber=62, createdTime=2023-06-24, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26ce3279712, moduleTitle=2021年度HR阳性晚期乳腺癌治疗进展总结, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f26ce3279712)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=Clin Cancer Res：氟维司群+依维莫司+阿纳曲唑联合作一线治疗HR阳性晚期乳腺癌的效果, objectType=article, longId=221476, objectId=bf402214e67f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf402214e67f, replyNumber=0, likeNumber=0, createdTime=2022-04-14, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf402214e67f, moduleTitle=Clin Cancer Res：氟维司群+依维莫司+阿纳曲唑联合作一线治疗HR阳性晚期乳腺癌的效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bf402214e67f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954155, encodeId=132419541551b, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌, objectType=article, longId=215465, objectId=b32a2154654f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b32a2154654f, replyNumber=0, likeNumber=88, createdTime=2021-11-03, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b32a2154654f, moduleTitle=J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b32a2154654f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954154, encodeId=38b8195415447, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=晚期乳腺癌：Verzenio显著提高了HR阳性/HER2阴性患者的生存率, objectType=article, longId=176547, objectId=81d61e65477b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81d61e65477b, replyNumber=0, likeNumber=67, createdTime=2020-05-11, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81d61e65477b, moduleTitle=晚期乳腺癌：Verzenio显著提高了HR阳性/HER2阴性患者的生存率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=81d61e65477b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954153, encodeId=05b1195415392, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=HR阳性乳腺癌内分泌治疗进展, objectType=article, longId=175259, objectId=f8b81e52593e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8b81e52593e, replyNumber=0, likeNumber=84, createdTime=2019-11-12, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8b81e52593e, moduleTitle=HR阳性乳腺癌内分泌治疗进展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f8b81e52593e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954152, encodeId=7fc2195415275, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=Lancet oncol：瑞博悉尼联合内分泌疗法治疗绝经后的HR阳性的、HER2阴性的晚期乳腺癌患者可获得良好疗效, objectType=article, longId=139131, objectId=69251391318d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69251391318d, replyNumber=0, likeNumber=69, createdTime=2018-09-14, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69251391318d, moduleTitle=Lancet oncol：瑞博悉尼联合内分泌疗法治疗绝经后的HR阳性的、HER2阴性的晚期乳腺癌患者可获得良好疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=69251391318d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954150, encodeId=f0d81954150a4, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=【名家论道】余科达教授：OFS在绝经前HR阳性EBC的研究回顾与应用探索（上）, objectType=article, longId=117651, objectId=60f411e65171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60f411e65171, replyNumber=0, likeNumber=78, createdTime=2018-03-27, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60f411e65171, moduleTitle=【名家论道】余科达教授：OFS在绝经前HR阳性EBC的研究回顾与应用探索（上）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=60f411e65171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954151, encodeId=446b1954151f2, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=【名家论道】余科达教授：OFS在绝经前HR阳性EBC的研究回顾与应用探索（下）, objectType=article, longId=118518, objectId=0a51118518a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a51118518a5, replyNumber=0, likeNumber=77, createdTime=2018-07-22, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a51118518a5, moduleTitle=【名家论道】余科达教授：OFS在绝经前HR阳性EBC的研究回顾与应用探索（下）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0a51118518a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954149, encodeId=86921954149c0, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, objectTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, objectType=article, longId=79604, objectId=a2e5e960448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e5e960448, replyNumber=0, likeNumber=77, createdTime=2017-05-10, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e5e960448, moduleTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a2e5e960448)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HR阳性

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

2021年度HR阳性晚期乳腺癌治疗进展总结

2023-06-24

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

Clin Cancer Res：氟维司群+依维莫司+阿纳曲唑联合作一线治疗HR阳性晚期乳腺癌的效果

2022-04-14

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌

2021-11-03

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

晚期乳腺癌：Verzenio显著提高了HR阳性/HER2阴性患者的生存率

2020-05-11

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

HR阳性乳腺癌内分泌治疗进展

2019-11-12

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

Lancet oncol：瑞博悉尼联合内分泌疗法治疗绝经后的HR阳性的、HER2阴性的晚期乳腺癌患者可获得良好疗效

2018-09-14

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

【名家论道】余科达教授：OFS在绝经前HR阳性EBC的研究回顾与应用探索（上）

2018-03-27

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

【名家论道】余科达教授：OFS在绝经前HR阳性EBC的研究回顾与应用探索（下）

2018-07-22

仁医06 (审核中...)

前往app查看评论内容

#HR阳性#

NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期

2017-05-10

科室
- - 订阅+
  - 更多科室
工具
服务